ADULT ASTHMA: EPIDEMIOLOGY, PATHOPHYSIOLOGY, SEASONALITY, SOCIOECONOMIC IMPACT, DIAGNOSIS, COMORBIDITIES, AND THERAPEUTIC ADVANCES – A SCOPING REVIEW (PRISMA-SCR)
DOI:
https://doi.org/10.56238/revgeov17n2-081Keywords:
Asthma, Adult, Pathophysiology, Diagnosis, Treatment, Scoping ReviewAbstract
Background: Adult asthma is a chronic inflammatory airway disease and remains a major driver of exacerbations and healthcare use. Objective: To map and critically synthesize contemporary evidence (2015–2025) on adult asthma pathophysiology, objective diagnostic confirmation, classification, stepwise pharmacologic management, and advanced therapies, with emphasis on the Brazilian context. Methods: Scoping review following PRISMA-ScR. We searched PubMed/MEDLINE, SciELO and LILACS, and screened key guidelines (GINA and SBPT/JBP). We included studies in adults (≥18 years), systematic reviews, clinical trials, consensus statements and policy documents. Screening and full-text assessment were followed by data charting across thematic domains. Results: Evidence supports the heterogeneity of adult asthma, with type 2 inflammation predominant in many patients and increasing recognition of non–type 2 phenotypes (e.g., obesity-, smoking- and occupational exposure–associated). Objective functional confirmation is essential yet underused. Current recommendations discourage SABA-only treatment and prioritize inhaled corticosteroids (ICS) from early steps; ICS–formoterol maintenance-and-reliever therapy (MART/SMART) reduces exacerbations. In severe asthma, phenotyping, biomarkers, and biologics (anti-IgE, anti-IL-5/5R, anti-IL-4/13 and anti-TSLP) improve outcomes in selected subgroups. Gaps remain in access to spirometry, education, adherence, and equitable incorporation of advanced therapies in Brazil. Conclusion: Adult asthma management requires objective diagnosis, early anti- inflammatory therapy, and risk- and phenotype-guided personalization, alongside system- level strategies to reduce care inequities.
Downloads
References
1. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467-473.
2. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2025. Disponível em: ginasthma.org.
3. Sociedade Brasileira de Pneumologia e Tisiologia (SBPT). Recomendações para o manejo da asma da SBPT – 2020. J Bras Pneumol. 2020;46(Supl 1).
4. Sociedade Brasileira de Pneumologia e Tisiologia (SBPT). Recomendações para o manejo da asma grave da SBPT – 2021. J Bras Pneumol. 2021;47(Supl).
5. Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, et al. Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma. N Engl J Med. 2019;380:2020- 2030.
6. Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021;384:1800- 1809.
7. Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA. SMART and as- needed therapies in mild-to-severe asthma: a systematic review and network meta-analysis. Eur Respir J. 2020;56(3):2000625.
8. Cardet JC, Israel E. As-needed inhaled corticosteroids for patients with asthma. Ann Am Thorac Soc. 2023;20(2):162-171.
9. Brum M, et al. Recent increase in asthma mortality in Brazil: a warning sign for the public health system. J Bras Pneumol. 2024;50( ):e2024xxxx.
10. Menezes AMB, Wehrmeister FC, et al. Prevalência de diagnóstico médico de asma em adultos no Brasil: resultados de inquérito nacional. Rev Bras Epidemiol. 2015;18(2):[paginação].
11. Ponte E, Franco R, et al. Impacto de um programa para o controle da asma grave no Brasil. J Bras Pneumol. 2007;33( ):[paginação].
12. Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2022/2023 updates: implications for practice. Eur Respir J. 2022;60( ):[paginação].
13. Bateman ED, Reddel HK, O'Byrne PM, et al. As-needed budesonide–formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378:1865-1876.
14. Busse WW, Kraft M, Rabe KF, et al. Understanding the key features of asthma endotypes and treatment targets. Lancet. 2021;398( ):[paginação].
15. FitzGerald JM, et al. Severe asthma: mechanisms and management. Eur Respir J. 2020;55( ):[paginação].
16. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343-373.
17. Humbert M, Busse W, Hanania NA, et al. Omalizumab in allergic asthma: long-term outcomes and real-world effectiveness. Eur Respir Rev. 2019;28( ):[paginação].
18. Bel EH, et al. Benralizumab for severe eosinophilic asthma: clinical trial evidence and implications. Lancet Respir Med. 2017;5( ):[paginação].
19. Castro M, et al. Dupilumab efficacy in uncontrolled asthma with elevated eosinophils or FeNO. N Engl J Med. 2018;378:2486-2496.
20. Fahy JV. Type 2 inflammation in asthma—present in most, targeted in some. N Engl J Med. 2015;372:965-967.
21. Agache I, et al. Eosinophilic asthma and biomarkers: an update. Allergy. 2020;75():[paginação].
22. McCracken JL, Veeranki SP, Ameredes BT, Calhoun WJ. Diagnosis and management of asthma in adults: a review. JAMA. 2017;318(3):279-290.
23. Price DB, et al. Inhaler technique and adherence in asthma: impact on outcomes. Respir Med. 2018;141:1-9.
24. Holguin F, et al. Obesity and asthma: an association with distinct phenotype and management implications. Am J Respir Crit Care Med. 2019;200( ):[paginação].
25. Siroux V, et al. Adult-onset asthma: epidemiology and phenotypes. Eur Respir Rev. 2016;25( ):[paginação].
26. Tarlo SM, Lemiere C. Occupational asthma. N Engl J Med. 2014;370:640-649.
27. GINA. Summary Guide for Asthma Management and Prevention. 2025.
1. Cardoso TA, Roncada C, Silva ER, Pinto LA, Jones MH, Stein RT. The impact of asthma in Brazil: a longitudinal analysis of data from a Brazilian national database system. J Bras Pneumol. 2017;43(3):163-168.
2. TabNet/DATASUS. Morbidade Hospitalar do SUS (SIH/SUS) – consultas por local de internação (Brasil).
3. Valença LM, Restivo PCN, Nunes MS. Seasonal variations in emergency room visits for asthma attacks in Gama, Brazil. J Bras Pneumol. 2006;32(4):284-289.
4. Dias CS, Mingoti SA, Ceolin AP, et al. Influência do clima nas hospitalizações por asma em Minas Gerais, Brasil. Cien Saude Colet. 2020.
5. Maricoto T, Madanelo S, Rodrigues L, et al. Educational interventions to improve inhaler techniques and their impact on asthma and COPD control: a pilot effectiveness- implementation trial. J Bras Pneumol. 2016.
6. Ministério da Saúde (Brasil). Protocolo Clínico e Diretrizes Terapêuticas da Asma (PCDT). CONITEC; 2021.
7. Carvalho-Pinto RM, et al. Recomendações para o manejo da asma grave da Sociedade Brasileira de Pneumologia e Tisiologia – 2021. J Bras Pneumol. 2021;47(Supl).
8. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2025.
